Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis
- PMID: 23600998
- PMCID: PMC3783926
- DOI: 10.1089/thy.2012.0563
Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis
Abstract
Background: Tall cell variant (TCV) and diffuse sclerosing variant (DSV) of papillary thyroid cancer are aggressive subtypes, for which tumors ≤1 cm have not been exclusively studied.
Methods: The SEER database (1988-2009) was used to compare characteristics of TCV ≤1 cm (mTCV) and DSV ≤1 cm (mDSV) with classic papillary thyroid microcarcinoma (mPTC). Survival was analyzed with the Kaplan-Meier method and log-rank test, and risk factors for nodal metastases with chi-square analysis and binary logistic regression.
Results: There were 97 mTCV, 90 mDSV, and 18,260 mPTC patients. mTCV incidence increased by 79.9% (p=0.153) over the study period, while mDSV incidence decreased by 10.3% (p=0.315). Compared to classic mPTC, mTCV tended to be larger on average (7.1 mm vs. 5.3 mm, p<0.001), with higher rates of multifocality (47.2% vs. 34.0% respectively, p=0.018) and lymph-node examination (63.9% vs. 39.2% respectively, p<0.001), while in mDSV, nodal metastases were more frequent (57.1% vs. 33.1% respectively, p=0.007). Both aggressive variants had higher rates of extrathyroidal extension (27.8% mTCV vs. 13.3% mDSV vs. 6.1% mPTC, p<0.001). Aggressive variants also received radioactive iodine more frequently (39.2% mTCV vs. 40.0% mDSV vs. 29.1% mPTC, p<0.001). However, they were not statistically more likely to receive thyroidectomy over lobectomy compared to classic mPTC. There were no significant differences in overall and disease-specific survival between the histologies. In mTCV, after adjustment, extrathyroidal extension was independently associated with size >7 mm (odds ratio (OR) 4.4 [CI 1.5-13.6]) and nodal metastasis with multifocality (OR 5.4 [CI 1.3-23.4]) and extrathyroidal extension (OR 5.8 [CI 1.3-25.4]). No statistically significant predictors of extrathyroidal extension or nodal metastasis in mDSV were observed.
Conclusions: Aggressive variants of mPTC tend to exhibit more aggressive pathologic characteristics than classic mPTC, but survival appears to be similar. Treatment with total thyroidectomy and central lymphadenectomy may be warranted if the diagnosis can be made pre- or intraoperatively.
Figures
Similar articles
-
Aggressive variants of papillary thyroid microcarcinoma are associated with high-risk features, but not decreased survival.Surgery. 2020 Jan;167(1):19-27. doi: 10.1016/j.surg.2019.03.030. Epub 2019 Oct 16. Surgery. 2020. PMID: 31627846
-
Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients.Ann Surg Oncol. 2012 Jun;19(6):1874-80. doi: 10.1245/s10434-011-2129-x. Epub 2011 Nov 8. Ann Surg Oncol. 2012. PMID: 22065195
-
Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.Surgery. 2022 Jan;171(1):203-211. doi: 10.1016/j.surg.2021.05.054. Epub 2021 Aug 10. Surgery. 2022. PMID: 34384604
-
Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.J Clin Endocrinol Metab. 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. J Clin Endocrinol Metab. 2023. PMID: 36546348 Free PMC article. Review.
-
A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.Oncotarget. 2017 Jan 24;8(4):6222-6232. doi: 10.18632/oncotarget.14055. Oncotarget. 2017. PMID: 28009980 Free PMC article. Review.
Cited by
-
Choice of management strategy for papillary thyroid microcarcinoma: active surveillance or immediate surgery?J Cancer. 2024 Jan 1;15(4):1009-1020. doi: 10.7150/jca.91612. eCollection 2024. J Cancer. 2024. PMID: 38230222 Free PMC article. Review.
-
A novel nomogram for identifying high-risk patients among active surveillance candidates with papillary thyroid microcarcinoma.Front Endocrinol (Lausanne). 2023 Sep 15;14:1185327. doi: 10.3389/fendo.2023.1185327. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37780614 Free PMC article.
-
Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer.Ann Surg Oncol. 2023 Aug;30(8):4761-4770. doi: 10.1245/s10434-023-13589-y. Epub 2023 May 8. Ann Surg Oncol. 2023. PMID: 37154968
-
The Significance of Unsampled Microscopic Thyroid Carcinomas in Multinodular Goiter.Endocr Pathol. 2023 Mar;34(1):119-128. doi: 10.1007/s12022-022-09743-z. Epub 2022 Dec 17. Endocr Pathol. 2023. PMID: 36527546
-
A nomogram and risk classification system for predicting cancer-specific survival in tall cell variant of papillary thyroid cancer: a SEER-based study.J Endocrinol Invest. 2023 May;46(5):893-901. doi: 10.1007/s40618-022-01949-6. Epub 2022 Nov 15. J Endocrinol Invest. 2023. PMID: 36376545
References
-
- Davies L. Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167. - PubMed
-
- Chen AY. Jemal A. Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–3807. - PubMed
-
- Hughes DT. Haymart MR. Miller BS. Gauger PG. Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231–236. - PubMed
-
- Sugitani I. Toda K. Yamada K. Yamamoto N. Ikenaga M. Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222–1231. - PubMed
-
- Yu XM. Wan Y. Sippel RS. Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254:653–660. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
